

Ref. No: 1283  
Date: 17/10/24  
Subject: High-cost drugs in ophthalmology

## REQUEST

I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following questions will be highly appreciated.

1. For the 4 months from May to August 2024, how many unique patients received the following intra-vitreous treatments for any eye condition:

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab – Ongavia

Ranibizumab - Ximluci

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

## Ranibizumab – Ongavia

## Ranibizumab - Ximluci

### RESPONSE

MWL response.

No of patients May – August 2024

#### Aflibercept

Time Interval	Patients	Eyes	Injections
May-24	427	517	279
Jun-24	409	513	223
Jul-24	457	567	275
Aug-24	414	525	259
<b>Total</b>	<b>762</b>	<b>937</b>	<b>1036</b>

#### Bevacizumab

Time Interval	Patients	Eyes	Injections
May-24	0	0	0
Jun-24	0	0	0
Jul-24	1	1	0
Aug-24	0	0	0
<b>Total</b>	<b>1</b>	<b>1</b>	<b>0</b>

#### Brolucizumab

Time Interval	Patients	Eyes	Injections
May-24	4	4	0
Jun-24	2	2	2
Jul-24	1	1	0
Aug-24	3	3	2
<b>Total</b>	<b>5</b>	<b>5</b>	<b>4</b>

Dexamethasone

Time Interval	Patients	Eyes	Injections
May-24	27	28	6
Jun-24	36	39	8
Jul-24	32	34	13
Aug-24	25	26	3
<b>Total</b>	<b>59</b>	<b>63</b>	<b>30</b>

Faricimab

Time Interval	Patients	Eyes	Injections
May-24	100	119	94
Jun-24	113	133	107
Jul-24	129	155	124
Aug-24	105	134	108
<b>Total</b>	<b>178</b>	<b>213</b>	<b>433</b>

Ranibizumab – Lucentis

Time Interval	Patients	Eyes	Injections
May-24	117	129	0
Jun-24	118	130	0
Jul-24	109	118	0
Aug-24	80	88	0
<b>Total</b>	<b>240</b>	<b>267</b>	<b>0</b>

Ranibizumab – Ongavia

Time Interval	Patients	Eyes	Injections
May-24	182	208	120
Jun-24	178	202	119
Jul-24	187	205	125
Aug-24	171	193	99
<b>Total</b>	<b>292</b>	<b>325</b>	<b>463</b>

Ranibizumab – Ximluci - 0

## Q2 Report ran for 1<sup>st</sup> injections.

[Home](#) > [Medical Retina](#) > Number of Patients Eyes and Injections

Indication Group(s) at 1st Injection	nAMD,DMO,RVO,Myopic CNV,Other	Indication(s) at 1st Injection	nAMD - age-related macular degenera
1st Injection Age Range(s)	≤ 30,31 to 50,51 to 60,61 to 70,71 to 80	Injected Drug Group(s)	Anti-VEGF,Steroid
Injected Drug(s)	Anti-VEGF - Ranibizumab (Lucentis),An	Current Diabetic Status	Not Diabetic,Not Known
Hospital(s)	St Helens Hospital	Laser Prior to 1st Injection	No Prior Laser
Year From	2024	Month From	May
Year To	2024	Month To	August
Time Interval	Month	Display Type	Patients, Eyes and Injections
Additional Criteria	No Additional Criteria		